Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Neuraxis, Inc. (NRXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NRXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.88
1 Year Target Price $5.88
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.46% | Avg. Invested days 53 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.10M USD | Price to earnings Ratio - | 1Y Target Price 5.88 |
Price to earnings Ratio - | 1Y Target Price 5.88 | ||
Volume (30-day avg) 1 | Beta 3.1 | 52 Weeks Range 1.33 - 3.99 | Updated Date 09/16/2025 |
52 Weeks Range 1.33 - 3.99 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -222.91% | Operating Margin (TTM) -190.85% |
Management Effectiveness
Return on Assets (TTM) -83.58% | Return on Equity (TTM) -2480.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18318036 | Price to Sales(TTM) 7.18 |
Enterprise Value 18318036 | Price to Sales(TTM) 7.18 | ||
Enterprise Value to Revenue 5.69 | Enterprise Value to EBITDA -4.39 | Shares Outstanding 9872780 | Shares Floating 7459992 |
Shares Outstanding 9872780 | Shares Floating 7459992 | ||
Percent Insiders 20.39 | Percent Institutions 8.55 |
Upturn AI SWOT
Neuraxis, Inc.
Company Overview
History and Background
Neuraxis, Inc., founded in 2004, is a medical technology company focused on developing and marketing innovative products to diagnose and treat neurological disorders. Initially focused on neurostimulation devices, it has expanded into neuromonitoring and diagnostics.
Core Business Areas
- Neurostimulation: Designs and manufactures implantable neurostimulation systems for pain management and movement disorders.
- Neuromonitoring: Offers monitoring solutions for surgical procedures involving the nervous system, aiming to improve patient outcomes.
- Neurodiagnostics: Develops diagnostic tools for identifying and assessing neurological conditions.
Leadership and Structure
The company is led by a CEO with extensive experience in the medical device industry. The organizational structure consists of functional departments including R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Axon Therapy System: An implantable spinal cord stimulation (SCS) system for chronic pain management. Limited market share details are available publicly, but competes with Medtronic, Boston Scientific, and Abbott. A significant portion of their revenue is attributed to this product, estimated at $50 million annually. Competitors: Medtronic (MDT), Boston Scientific (BSX), Abbott (ABT)
- NerveTrack Monitoring System: A real-time intraoperative nerve monitoring system. Competitors: Medtronic (MDT), NuVasive (NUVA)
Market Dynamics
Industry Overview
The neuromodulation and monitoring market is experiencing steady growth driven by an aging population and increasing prevalence of neurological disorders. Technological advancements are also contributing to market expansion.
Positioning
Neuraxis, Inc. is a mid-sized player in the neuromodulation and monitoring market, focusing on innovation and specialized applications.
Total Addressable Market (TAM)
The global neuromodulation market is projected to reach $13.3 billion by 2027. Neuraxis, Inc. aims to capture a larger share of this market through product development and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong focus on specialized applications
- Established relationships with key opinion leaders
Weaknesses
- Limited brand recognition compared to larger competitors
- Dependence on key products
- Smaller sales and marketing team
Opportunities
- Expanding into new geographic markets
- Developing partnerships with hospitals and clinics
- Acquiring complementary technologies
Threats
- Increasing competition from larger players
- Regulatory changes and reimbursement pressures
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
- NUVA
Competitive Landscape
Neuraxis, Inc. competes with larger, more established players in the neuromodulation and monitoring market. The company differentiates itself through product innovation and a focus on specialized applications. However, they need to be able to achieve a larger scale like Medtronic.
Major Acquisitions
NeuroTech Solutions
- Year: 2018
- Acquisition Price (USD millions): 75
- Strategic Rationale: Acquired NeuroTech Solutions to expand its product portfolio and geographic reach.
Growth Trajectory and Initiatives
Historical Growth: Neuraxis, Inc. has experienced steady growth in recent years driven by product innovation and market expansion.
Future Projections: Analysts project continued revenue growth in the coming years, driven by new product launches and increasing market penetration.
Recent Initiatives: The company recently launched a new neurostimulation device and expanded its sales force in Europe.
Summary
Neuraxis, Inc. is a growing medical device company with a focus on neuromodulation and monitoring. Its innovative products and strong financial performance are positives. The company needs to be able to compete against the larger firms. Future growth depends on successful new product launches and strategic partnerships to grow its market penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuraxis, Inc.
Exchange NYSE MKT | Headquaters Carmel, IN, United States | ||
IPO Launch date 2023-08-09 | President, CEO & Director Mr. Brian Carrico | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://neuraxis.com |
Full time employees 21 | Website https://neuraxis.com | ||
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.